India's Biocon updates on biosimilar paths after strong Q1

India street scene

Bangalore-based Biocon is on track to file biosimilar approval applications for pegfilgrastim (Neulasta) in the U.S. and insulin glargine (Lantus), trastuzumab (Herceptin) and adalimumab (Humira) in the U.S. and European Union within the company's fiscal year.

That was the word from Managing Director Kiran Mazumdar-Shaw on the July 21 earnings call for the first quarter, which ended June 30.

The update and the state of play with sales and development partner Mylan ($MYL) in the space capped a strong quarter for the company. Biocon launched a Lantus biosimilar in Japan this summer and said last week that the European Medicines Agency will be reviewing an application for the marketing authorization of a biosimilar of pegfilgrastim.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

"As a part of our global biosimilar foray, our partner Mylan filed the Marketing Authorization Application, or MAA, for biosimilar pegfilgrastim for the EU markets in Q1, which has been accepted by the EMA, European Medical Agency," Mazumdar-Shaw noted.

"The application will undergo the review process and this kicks off the process of filing of multiple biosimilar applications over the course of this fiscal (year)."

The company reported a 17% gain in net profit to INR1.47 billion ($22 million) and a revenue increase of 11% to INR9.5 billion ($141 million), with sales in of biologics up 53% on the emerging markets business.

An unidentified executive on the call said that in the case of trastuzumab, clinical results for the application are scheduled to be presented at the European Society of Medical Oncology Annual Congress, slated to be held in Copenhagen in October.

Roche ($RHBBY) and Biocon are involved in a legal dispute over a Herceptin biosimilar in India that hinges on the use of clinical data in the label that the Swiss-based firm says come from its work.

- here's the release from Biocon

Related Articles:
EMA to review Biocon, Mylan pegfilgrastim biosimilar for marketing authorization
Lawyers for Roche, Biocon trade contempt charges in Herceptin biosim case
India's Biocon chief notes plans for biosimilar plays in EU, U.S.


Suggested Articles

AstraZeneca has had high hopes for its Imfinzi-tremelimumab pairing. But after a high-profile miss last year, the combo has struck out again.

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

Kinase inhibitors to treat cancer have driven nearly $100 billion in deals since 2010, a trend that's likely to grow, SVB Leerink analysts predict.